Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital

Sonoma Pharmaceuticals ( (SNOA) ) just unveiled an announcement.

On April 24, 2026, Sonoma Pharmaceuticals, Inc., a Nasdaq-listed HOCl-focused healthcare company, entered into an underwriting agreement with Dawson James Securities for a public equity offering comprised of units of common stock or pre-funded warrants plus accompanying warrants. The deal priced at $1.35 per unit, with a 45-day over-allotment option for additional shares and warrants, and included customary underwriting fees, expense allowances and lock-up agreements for the company’s executives and directors.

The offering, which closed on April 27 and 28, 2026 following SEC effectiveness of the registration statement, resulted in the sale of 1,650,716 shares, 1,312,247 pre-funded warrants and 3,407,404 warrants, generating expected net proceeds of about $3.5 million for general corporate purposes and working capital. Sonoma also executed warrant agency agreements with Computershare entities to administer the new pre-funded warrants and warrants, underscoring the company’s continued reliance on capital markets to fund operations and support its global HOCl product portfolio.

Spark’s Take on SNOA Stock

According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses and cash burn) and bearish technicals (price well below major moving averages and negative MACD). A positive offset comes from the Kenvue supply agreement, which improves commercial visibility, but valuation remains constrained by lack of profitability.

To see Spark’s full report on SNOA stock, click here.

More about Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. is a global healthcare company specializing in stabilized hypochlorous acid (HOCl) technology for wound care, eye care, dermatology, podiatry, animal health and non-toxic disinfectants. Its clinically proven products, which are sold directly and through partners in 55 countries, are supported by manufacturing in Guadalajara, Mexico and commercial hubs in Boulder, Colorado and Roermond, Netherlands.

The company’s HOCl-based therapies are positioned to address skin abrasions, lacerations, minor irritations, cuts and intact skin while reducing itch, pain, scarring and irritation without damaging healthy tissue. Sonoma actively expands its international distribution network to deepen market penetration across medical and consumer health segments.

Average Trading Volume: 148,974

Technical Sentiment Signal: Sell

Current Market Cap: $1.85M

Learn more about SNOA stock on TipRanks’ Stock Analysis page.